

Santica M Marcovina, Scd

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6758969/publications.pdf>

Version: 2024-02-01

91
papers

9,848
citations

57631

44
h-index

43802

91
g-index

92
all docs

92
docs citations

92
times ranked

9555
citing authors

#	ARTICLE	IF	CITATIONS
1	Lipoprotein(a): A Genetically Determined, Causal, and Prevalent Risk Factor for Atherosclerotic Cardiovascular Disease: A Scientific Statement From the American Heart Association. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2022, 42, ATV00000000000000147.	1.1	207
2	The Impact of Racial and Ethnic Health Disparities in Diabetes Management on Clinical Outcomes: A Reinforcement Learning Analysis of Health Inequity Among Youth and Young Adults in the SEARCH for Diabetes in Youth Study. <i>Diabetes Care</i> , 2022, 45, 108-118.	4.3	15
3	Sortilin enhances secretion of apolipoprotein(a) through effects on apolipoprotein B secretion and promotes uptake of lipoprotein(a). <i>Journal of Lipid Research</i> , 2022, 63, 100216.	2.0	4
4	Development and validation of an isoform-independent monoclonal antibody-based ELISA for measurement of lipoprotein(a). <i>Journal of Lipid Research</i> , 2022, 63, 100239.	2.0	10
5	Longitudinal Changes in Arterial Stiffness and Heart Rate Variability in Youth-Onset Type 1 Versus Type 2 Diabetes: The SEARCH for Diabetes in Youth Study. <i>Diabetes Care</i> , 2022, 45, 1647-1656.	4.3	6
6	Twenty years of pediatric diabetes surveillance: what do we know and why it matters. <i>Annals of the New York Academy of Sciences</i> , 2021, 1495, 99-120.	1.8	18
7	Development of an LC-MS/MS Proposed Candidate Reference Method for the Standardization of Analytical Methods to Measure Lipoprotein(a). <i>Clinical Chemistry</i> , 2021, 67, 490-499.	1.5	40
8	Prevalence and influence of LPA gene variants and isoform size on the Lp(a)-lowering effect of pelacarsen. <i>Atherosclerosis</i> , 2021, 324, 102-108.	0.4	19
9	The relationship between traffic-related air pollution exposures and allostatic load score among youth with type 1 diabetes in the SEARCH cohort. <i>Environmental Research</i> , 2021, 197, 111075.	3.7	4
10	Trends in Prevalence of Type 1 and Type 2 Diabetes in Children and Adolescents in the US, 2001-2017. <i>JAMA - Journal of the American Medical Association</i> , 2021, 326, 717.	3.8	254
11	Genome-wide Association Study of Lipid Traits in Youth With Type 2 Diabetes. <i>Journal of the Endocrine Society</i> , 2021, 5, bvab139.	0.1	2
12	Glycemic control is associated with dyslipidemia over time in youth with type 2 diabetes: The SEARCH for diabetes in youth study. <i>Pediatric Diabetes</i> , 2021, 22, 951-959.	1.2	7
13	PPARA Polymorphism Influences the Cardiovascular Benefit of Fenofibrate in Type 2 Diabetes: Findings From ACCORD-Lipid. <i>Diabetes</i> , 2020, 69, 771-783.	0.3	28
14	Characterizing the weight-glycemia phenotypes of type 1 diabetes in youth and young adulthood. <i>BMJ Open Diabetes Research and Care</i> , 2020, 8, e000886.	1.2	5
15	Analytical Performance Specifications for Lipoprotein(a), Apolipoprotein B-100, and Apolipoprotein A-I Using the Biological Variation Model in the EuBIVAS Population. <i>Clinical Chemistry</i> , 2020, 66, 727-736.	1.5	17
16	PCSK9 Inhibition with alirocumab increases the catabolism of lipoprotein(a) particles in statin-treated patients with elevated lipoprotein(a). <i>Metabolism: Clinical and Experimental</i> , 2020, 107, 154221.	1.5	46
17	Progression to hypertension in youth and young adults with type 1 or type 2 diabetes: The SEARCH for Diabetes in Youth Study. <i>Journal of Clinical Hypertension</i> , 2020, 22, 888-896.	1.0	20
18	The association of low-density lipoprotein cholesterol with elevated arterial stiffness in adolescents and young adults with type 1 and type 2 diabetes: The SEARCH for Diabetes in Youth study. <i>Pediatric Diabetes</i> , 2020, 21, 863-870.	1.2	9

#	ARTICLE	IF	CITATIONS
19	Inflammation and acute traffic-related air pollution exposures among a cohort of youth with type 1 diabetes. <i>Environment International</i> , 2019, 132, 105064.	4.8	19
20	Apolipoprotein(a) Kinetics in Statin-Treated Patients With Elevated Plasma Lipoprotein(a) Concentration. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2019, 104, 6247-6255.	1.8	16
21	PCSK9 loss-of-function variants and Lp(a) phenotypes among black US adults. <i>Journal of Lipid Research</i> , 2019, 60, 1946-1952.	2.0	8
22	Burden of Cardiovascular Risk Factors Over Time and Arterial Stiffness in Youth With Type 1 Diabetes Mellitus: The SEARCH for Diabetes in Youth Study. <i>Journal of the American Heart Association</i> , 2019, 8, e010150.	1.6	50
23	Lipoprotein(a) Particle Production as a Determinant of Plasma Lipoprotein(a) Concentration Across Varying Apolipoprotein(a) Isoform Sizes and Background Cholesterol-Lowering Therapy. <i>Journal of the American Heart Association</i> , 2019, 8, e011781.	1.6	40
24	Co-occurrence of early diabetes-related complications in adolescents and young adults with type 1 diabetes: an observational cohort study. <i>The Lancet Child and Adolescent Health</i> , 2019, 3, 35-43.	2.7	36
25	Relations of GlycA and lipoprotein particle subspecies with cardiovascular events and mortality: A post hoc analysis of the AIM-HIGH trial. <i>Journal of Clinical Lipidology</i> , 2018, 12, 348-355.e2.	0.6	41
26	Lipid Profiles, Inflammatory Markers, and Insulin Therapy in Youth with Type 2 Diabetes. <i>Journal of Pediatrics</i> , 2018, 196, 208-216.e2.	0.9	24
27	NHLBI Working Group Recommendations to Reduce Lipoprotein(a)-Mediated Risk of Cardiovascular Disease and Aortic Stenosis. <i>Journal of the American College of Cardiology</i> , 2018, 71, 177-192.	1.2	337
28	Lp(a) (Lipoprotein(a)) Levels Predict Progression of Carotid Atherosclerosis in Subjects With Atherosclerotic Cardiovascular Disease on Intensive Lipid Therapy. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2018, 38, 673-678.	1.1	32
29	Relationship between lipoprotein subfraction cholesterol and residual risk for cardiovascular outcomes: A post hoc analysis of the AIM-HIGH trial. <i>Journal of Clinical Lipidology</i> , 2018, 12, 741-747.e11.	0.6	6
30	Controlled study of the effect of proprotein convertase subtilisin-kexin type 9 inhibition with evolocumab on lipoprotein(a) particle kinetics. <i>European Heart Journal</i> , 2018, 39, 2577-2585.	1.0	116
31	Temporal variability in lipoprotein(a) levels in patients enrolled in the placebo arms of IONIS-APO(a)Rx and IONIS-APO(a)-LRx antisense oligonucleotide clinical trials. <i>Journal of Clinical Lipidology</i> , 2018, 12, 122-129.e2.	0.6	36
32	Modulation of GLP-1 Levels by a Genetic Variant That Regulates the Cardiovascular Effects of Intensive Glycemic Control in ACCORD. <i>Diabetes Care</i> , 2018, 41, 348-355.	4.3	16
33	Dietary quality and markers of inflammation: No association in youth with type 1 diabetes. <i>Journal of Diabetes and Its Complications</i> , 2018, 32, 179-184.	1.2	27
34	The early natural history of albuminuria in young adults with youth-onset type 1 and type 2 diabetes. <i>Journal of Diabetes and Its Complications</i> , 2018, 32, 1160-1168.	1.2	25
35	Genetic Tools for Coronary Risk Assessment in Type 2 Diabetes: A Cohort Study From the ACCORD Clinical Trial. <i>Diabetes Care</i> , 2018, 41, 2404-2413.	4.3	32
36	Impact of Apolipoprotein(a) Isoform Size on Lipoprotein(a) Lowering in the HPS2-THRIVE Study. <i>Circulation Genomic and Precision Medicine</i> , 2018, 11, e001696.	1.6	65

#	ARTICLE	IF	CITATIONS
37	A framework for selection of blood-based biomarkers for geroscience-guided clinical trials: report from the TAME Biomarkers Workgroup. <i>GeroScience</i> , 2018, 40, 419-436.	2.1	221
38	Relationship of lipoprotein(a) molar concentrations and mass according to lipoprotein(a) thresholds and apolipoprotein(a) isoform size. <i>Journal of Clinical Lipidology</i> , 2018, 12, 1313-1323.	0.6	66
39	Apolipoprotein(a) isoform size, lipoprotein(a) concentration, and coronary artery disease: a mendelian randomisation analysis. <i>Lancet Diabetes and Endocrinology</i> , 2017, 5, 524-533.	5.5	165
40	Incidence Trends of Type 1 and Type 2 Diabetes among Youths, 2002–2012. <i>New England Journal of Medicine</i> , 2017, 376, 1419-1429.	13.9	1,115
41	Serum cystatin C in youth with diabetes: The SEARCH for diabetes in youth study. <i>Diabetes Research and Clinical Practice</i> , 2017, 130, 258-265.	1.1	6
42	Effects of PCSK9 Inhibition With Alirocumab on Lipoprotein Metabolism in Healthy Humans. <i>Circulation</i> , 2017, 135, 352-362.	1.6	185
43	Prevalence of and Risk Factors for Diabetic Peripheral Neuropathy in Youth With Type 1 and Type 2 Diabetes: SEARCH for Diabetes in Youth Study. <i>Diabetes Care</i> , 2017, 40, 1226-1232.	4.3	202
44	Association of Type 1 Diabetes vs Type 2 Diabetes Diagnosed During Childhood and Adolescence With Complications During Teenage Years and Young Adulthood. <i>JAMA - Journal of the American Medical Association</i> , 2017, 317, 825.	3.8	471
45	Plasminogen promotes cholesterol efflux by the ABCA1 pathway. <i>JCI Insight</i> , 2017, 2, .	2.3	36
46	Roles of the low density lipoprotein receptor and related receptors in inhibition of lipoprotein(a) internalization by proprotein convertase subtilisin/kexin type 9. <i>PLoS ONE</i> , 2017, 12, e0180869.	1.1	40
47	Genetic Predictors of Cardiovascular Mortality During Intensive Glycemic Control in Type 2 Diabetes: Findings From the ACCORD Clinical Trial. <i>Diabetes Care</i> , 2016, 39, 1915-1924.	4.3	47
48	Antisense oligonucleotides targeting apolipoprotein(a) in people with raised lipoprotein(a): two randomised, double-blind, placebo-controlled, dose-ranging trials. <i>Lancet</i> , 2016, 388, 2239-2253.	6.3	584
49	The dose–response effect of insulin sensitivity on albuminuria in children according to diabetes type. <i>Pediatric Nephrology</i> , 2016, 31, 933-940.	0.9	11
50	Lipoprotein (a) measurements for clinical application. <i>Journal of Lipid Research</i> , 2016, 57, 526-537.	2.0	214
51	Arterial stiffness in adolescents and young adults with and without type 1 diabetes: the SEARCH CVD study. <i>Pediatric Diabetes</i> , 2015, 16, 367-374.	1.2	60
52	Mechanistic insights into Lp(a)-induced IL-8 expression: a role for oxidized phospholipid modification of apo(a). <i>Journal of Lipid Research</i> , 2015, 56, 2273-2285.	2.0	85
53	Antisense therapy targeting apolipoprotein(a): a randomised, double-blind, placebo-controlled phase 1 study. <i>Lancet</i> , 2015, 386, 1472-1483.	6.3	386
54	Heritability of Biomarkers of Oxidized Lipoproteins. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2015, 35, 1704-1711.	1.1	44

#	ARTICLE	IF	CITATIONS
55	Effects of Extended-Release Niacin on the Postprandial Metabolism of Lp(a) and ApoB-100-Containing Lipoproteins in Statin-Treated Men With Type 2 Diabetes Mellitus. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2015, 35, 2686-2693.	1.1	45
56	Change in adiposity minimally affects the lipid profile in youth with recent onset type 1 diabetes. <i>Pediatric Diabetes</i> , 2015, 16, 280-286.	1.2	8
57	HDL is a Superior Predictor of Carotid Artery Disease in a Case-Control Cohort of 1725 Participants. <i>Journal of the American Heart Association</i> , 2014, 3, e000902.	1.6	35
58	The SEARCH for Diabetes in Youth Study: Rationale, Findings, and Future Directions. <i>Diabetes Care</i> , 2014, 37, 3336-3344.	4.3	334
59	Dairy fat intake is associated with glucose tolerance, hepatic and systemic insulin sensitivity, and liver fat but not β -cell function in humans. <i>American Journal of Clinical Nutrition</i> , 2014, 99, 1385-1396.	2.2	77
60	Prevalence of and Disparities in Barriers to Care Experienced by Youth with Type 1 Diabetes. <i>Journal of Pediatrics</i> , 2014, 164, 1369-1375.e1.	0.9	88
61	Serum ferritin is associated with non-alcoholic fatty liver disease and decreased β -cell function in non-diabetic men and women. <i>Journal of Diabetes and Its Complications</i> , 2014, 28, 177-184.	1.2	26
62	No association of dietary fiber intake with inflammation or arterial stiffness in youth with type 1 diabetes. <i>Journal of Diabetes and Its Complications</i> , 2014, 28, 305-310.	1.2	11
63	Comparison of four methods of analysis of lipoprotein particle subfractions for their association with angiographic progression of coronary artery disease. <i>Atherosclerosis</i> , 2014, 233, 713-720.	0.4	81
64	Translating the basic knowledge of mitochondrial functions to metabolic therapy: role of L-carnitine. <i>Translational Research</i> , 2013, 161, 73-84.	2.2	102
65	Cardiovascular Risk Factors Are Associated With Increased Arterial Stiffness in Youth With Type 1 Diabetes. <i>Diabetes Care</i> , 2013, 36, 3938-3943.	4.3	64
66	Reduced Heart Rate Variability Among Youth With Type 1 Diabetes. <i>Diabetes Care</i> , 2013, 36, 157-162.	4.3	81
67	Etiological Approach to Characterization of Diabetes Type. <i>Diabetes Care</i> , 2011, 34, 1628-1633.	4.3	160
68	Sugar-sweetened and diet beverage consumption is associated with cardiovascular risk factor profile in youth with type 1 diabetes. <i>Acta Diabetologica</i> , 2011, 48, 275-282.	1.2	49
69	Harmonization of Glutamic Acid Decarboxylase and Islet Antigen-2 Autoantibody Assays for National Institute of Diabetes and Digestive and Kidney Diseases Consortia. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2010, 95, 3360-3367.	1.8	244
70	Relationship of Oxidized Phospholipids on Apolipoprotein B-100 Particles to Race/Ethnicity, Apolipoprotein(a) Isoform Size, and Cardiovascular Risk Factors. <i>Circulation</i> , 2009, 119, 1711-1719.	1.6	117
71	Glycemic Control in Youth with Diabetes: The SEARCH for Diabetes in Youth Study. <i>Journal of Pediatrics</i> , 2009, 155, 668-672.e3.	0.9	340
72	Serum Lipids and Glucose Control. <i>JAMA Pediatrics</i> , 2007, 161, 159.	3.6	102

#	ARTICLE	IF	CITATIONS
73	Higher Prevalence of Elevated Albumin Excretion in Youth With Type 2 Than Type 1 Diabetes: The SEARCH for Diabetes in Youth Study. <i>Diabetes Care</i> , 2007, 30, 2593-2598.	4.3	138
74	Lipid abnormalities are prevalent in youth with type 1 and type 2 diabetes: The search for diabetes in youth study. <i>Journal of Pediatrics</i> , 2006, 149, 314-319.	0.9	189
75	Lipoprotein(a) and Apolipoprotein(a) Isoforms. <i>Circulation</i> , 2005, 111, 1471-1479.	1.6	58
76	Evaluation of lipoprotein(a) as a prothrombotic factor: progress from bench to bedside. <i>Current Opinion in Lipidology</i> , 2003, 14, 361-366.	1.2	88
77	A Critical Evaluation of the Role of Lp(a) in Cardiovascular Disease: Can Lp(a) Be Useful in Risk Assessment?. <i>Seminars in Vascular Medicine</i> , 2002, 02, 335-344.	2.1	37
78	Use of a Reference Material Proposed by the International Federation of Clinical Chemistry and Laboratory Medicine to Evaluate Analytical Methods for the Determination of Plasma Lipoprotein(a). <i>Clinical Chemistry</i> , 2000, 46, 1956-1967.	1.5	262
79	Genotypes and Phenotypes for Apolipoprotein E and Alzheimer Disease in the Honolulu-Asia Aging Study. <i>Clinical Chemistry</i> , 2000, 46, 1548-1554.	1.5	23
80	Antibodies to Glutamic Acid Decarboxylase and Peripheral Nerve Function in Type 1 Diabetes*. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2000, 85, 3297-3308.	1.8	19
81	Fish Intake, Independent of Apo(a) Size, Accounts for Lower Plasma Lipoprotein(a) Levels in Bantu Fishermen of Tanzania. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 1999, 19, 1250-1256.	1.1	45
82	Lipoprotein(a) Concentration and Apolipoprotein(a) Size. <i>Circulation</i> , 1999, 100, 1151-1153.	1.6	68
83	Atherogenic Dyslipidemia in HIV-Infected Individuals Treated With Protease Inhibitors. <i>Circulation</i> , 1999, 100, 700-705.	1.6	592
84	Lipoprotein(a) and coronary heart disease risk. <i>Current Cardiology Reports</i> , 1999, 1, 105-111.	1.3	31
85	Effect of Postmenopausal Hormone Therapy on Lipoprotein(a) Concentration. <i>Circulation</i> , 1998, 97, 979-986.	1.6	179
86	Apolipoprotein B and A-I values in 147 576 Swedish males and females, standardized according to the World Health Organization's International Federation of Clinical Chemistry First International Reference Materials. <i>Clinical Chemistry</i> , 1998, 44, 1641-1649.	1.5	126
87	The Apo(a) Gene is the Major Determinant of Variation in Plasma Lp(a) Levels in African Americans. <i>American Journal of Human Genetics</i> , 1997, 61, 402-417.	2.6	84
88	Serum distribution of lipoprotein(a) in African Americans and Nigerians: Potential evidence for a genotype-environmental effect. , 1997, 14, 157-168.		14
89	High plasma levels of apo(a) fragments in Caucasians and African-Americans with end-stage renal disease: implications for plasma Lp(a) assay. <i>Clinical Genetics</i> , 1997, 52, 387-392.	1.0	18
90	Lipoprotein(a) Assembly. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 1996, 16, 1559-1567.	1.1	76

#	ARTICLE	IF	CITATIONS
91	Determination of serum levels of complement component C4b-binding protein: influence of age and inflammation. International Journal of Clinical and Laboratory Research, 1992, 21, 171-175.	1.0	25